as 12-20-2024 4:00pm EST
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | HOUSTON |
Market Cap: | 30.7M | IPO Year: | N/A |
Target Price: | $19.00 | AVG Volume (30 days): | 91.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.09 | EPS Growth: | N/A |
52 Week Low/High: | $2.44 - $6.16 | Next Earning Date: | 11-14-2024 |
Revenue: | $5,395,849 | Revenue Growth: | 79.04% |
Revenue Growth (this year): | 35.94% | Revenue Growth (next year): | N/A |
MRKR Breaking Stock News: Dive into MRKR Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
GlobeNewswire
4 days ago
GlobeNewswire
4 days ago
GlobeNewswire
6 days ago
GlobeNewswire
13 days ago
Simply Wall St.
17 days ago
MT Newswires
a month ago
GlobeNewswire
a month ago
The information presented on this page, "MRKR Marker Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.